The UK Competition Authority secures disqualification of pharmaceutical company director for 5 years for breaching competition law (Amit Patel / Auden McKenzie / Amilco)

KEYWORDS
Reference

UK Competition Authority, Amit Patel / Auden McKenzie / Amilco, Press release, 4 June 2020

Pharma company director disqualified for competition law breaches* The CMA has secured the disqualification of pharmaceutical company director Amit Patel after he admitted his role in arrangements that broke competition law. Amit Patel has signed undertakings that ban him from holding a director role at any UK company for the next 5 years, in connection with his involvement in illegal arrangements during his time at Auden McKenzie (Pharma Division) Ltd and Amilco Ltd. Auden McKenzie From

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

UK Competition Authority, The UK Competition Authority secures disqualification of pharmaceutical company director for 5 years for breaching competition law (Amit Patel / Auden McKenzie / Amilco), 4 June 2020, e-Competitions Pay-for-delay agreements, Art. N° 95291

Visites 396

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues